133 related articles for article (PubMed ID: 30134184)
1. MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Respondek M; Beberok A; Rok J; Rzepka Z; Wrześniok D; Buszman E
Toxicol In Vitro; 2018 Dec; 53():126-135. PubMed ID: 30134184
[TBL] [Abstract][Full Text] [Related]
2. MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage.
Respondek M; Beberok A; Rzepka Z; Rok J; Wrześniok D
Fundam Clin Pharmacol; 2020 Feb; 34(1):20-31. PubMed ID: 31410885
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes.
Respondek M; Beberok A; Rzepka Z; Rok J; Wrześniok D
Pathol Oncol Res; 2020 Jul; 26(3):1465-1474. PubMed ID: 31432325
[TBL] [Abstract][Full Text] [Related]
4. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
5. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C
Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067
[TBL] [Abstract][Full Text] [Related]
6. An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Pawlowska E; Szczepanska J; Szatkowska M; Blasiak J
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562589
[TBL] [Abstract][Full Text] [Related]
7. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
9. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM
Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082
[TBL] [Abstract][Full Text] [Related]
10. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728
[TBL] [Abstract][Full Text] [Related]
11. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
13. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
14. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
17. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Alexiou GA; Gerogianni P; Vartholomatos E; Kyritsis AP
Cancer Invest; 2016 Nov; 34(10):489-495. PubMed ID: 27768402
[TBL] [Abstract][Full Text] [Related]
19. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
20. Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Hanif F; Perveen K; Malhi SM; Jawed H; Simjee SU
Toxicol In Vitro; 2018 Oct; 52():306-313. PubMed ID: 30003979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
